Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Directors Reaffirm Plan to Explore M&A, Divestiture

NEW YORK, May 18 (GenomeWeb News) - Tripos' board of directors have "reaffirmed [their] commitment" to explore options for spurring growth, including selling or merging the firm, going private, or separating its informatics and research businesses.

 

The comments were made yesterday during the company's annual stockholders' meeting. Also at the meeting, the firm's six directors were re-elected to another one-year term, and the board extended the 1996 Director Stock Compensation Plan.

 

Tripos has been exploring options for its future since at least January, when the company said it had retained financial advisory firm Seven Hills Partners to identify options to help it grow.

 

Two months earlier, Tripos announced the end   of its lucrative four-year collaboration with Pfizer.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.